Naarden, The Netherlands – 23 February 2022 – Forbion and BioGeneration Ventures (BGV), two leading European life sciences venture capital firms, today announce the completion of a EUR 5 million Series Seed financing round in Complement Therapeutics Ltd...
Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. The conference takes place in Milan 16-18 May. Participants can join the discussion physically in Milan, or attend from home via a digital pass. Click...
Virtual poster presentation shows complete tumor regression and high tolerability of a SYNtecan E™ based ADC SYNtecan E™ linker-payload is a potent exatecan-based, DNA topoisomerase 1 inhibitor developed by Synaffix Data underscores ability of Synaffix’s technologies...
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized...
Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of...
The four-year agreement provides benefits for portfolio companies of Forbion and BioGeneration Ventures (BGV) Lonza to provide de-risking, development and manufacturing services for large molecule biologics The agreement will streamline the gene to IND process,...
